For decades, pharmacological treatments for pattern hair loss (androgenetic alopecia) have forced patients into a difficult trade-off: take oral 5-alpha reductase inhibitors like finasteride that alter systemic sex hormones (rendering them largely unsuitable for premenopausal women and risking sexual side effects in men), or apply minoxidil, which frequently triggers scalp dermatitis and fails in individuals lacking the scalp sulfotransferase enzyme.
While scientists have long recognized that recombinant human erythropoietin (EPO) stimulates hair growth, administering whole EPO systemically poses severe clinical hazards by triggering excess red blood cell production (polycythemia) and cardiovascular complications. By using computational in silico modeling, the researchers isolated the precise regenerative binding motif of EPO while deleting its hematological triggers. The resulting designer peptide, MLPH, binds directly to erythropoietin receptors on dermal papilla cells to ignite an insulin-like growth factor-1 (IGF-1) cascade, driving rapid human hair shaft elongation and active anagen phase induction with zero hormonal disruption and zero erythropoietic activity.
What Is It and How Does It Work?
The therapeutic breakthrough centers on Selective Helix C-1 Erythropoietin Receptor (EPOR) Activation and Dermal Papilla IGF-1 Paracrine Induction—stimulating follicular hair matrix growth without altering circulating hormones or hematocrit levels.
-
The Problem with Full-Length Erythropoietin (EPO): EPO is a biological hormone known for stimulating red blood cell production in bone marrow, but its receptors (EPOR) are also expressed on human hair follicles. While applying EPO stimulates hair roots, utilizing full-length EPO carries serious risks of elevated hematocrit, blood thickening, and thromboembolic events.
-
Computational Extraction of the “Helix C-1” Domain: Using advanced structural modeling and amino acid sequence analysis, the research team identified Helix C-1 as the exact structural loop of EPO responsible for activating tissue-protective and regenerative signaling. They designed a compact, stable peptide variant termed MLPH that forms a helical conformation engineered to bind the tissue EPOR complex. Crucially, MLPH lacks the secondary binding sites required to trigger bone marrow erythropoiesis.
-
Direct Stimulation of the Dermal Papilla Command Center: When MLPH reaches the dermal papilla, it docks onto local EPOR complexes. This binding event stimulates intracellular phosphorylation cascades that sharply upregulate the synthesis and secretion of Insulin-like Growth Factor-1 (IGF-1).
-
Re-Igniting Anagen and Keratinocyte Proliferation: IGF-1 is an indispensable physiological promoter of human hair growth. Released from MLPH-stimulated dermal papilla cells, IGF-1 acts on adjacent hair matrix keratinocytes, switching dormant telogen follicles back into active anagen, suppressing cellular senescence, and accelerating fiber production.
The Science: Clear Results from the Biomedicine & Pharmacotherapy Investigation
The multi-institutional research consortium evaluated computational docking models, cultured primary human dermal papilla cells, and ex vivo living human scalp hair follicle organ cultures:
-
Dramatic Hair Shaft Elongation in Human Follicles: In ex vivo human scalp hair follicle organ culture assays, MLPH treatment triggered a statistically significant surge in hair shaft elongation compared to untreated controls, matching the regenerative potency of positive controls.
-
Direct Dependency on IGF-1 Signaling: Mechanistic pathway validation confirmed that the hair-lengthening effect of MLPH is driven through IGF-1. When investigators co-administered an IGF-1 receptor inhibitor, the pro-growth effect was blocked, confirming that MLPH acts through targeted paracrine signaling.
-
Elevated DPC Proliferation and Reduced Oxidative Stress: Cellular assays demonstrated that MLPH increased both metabolic activity and cell proliferation within primary human dermal papilla cells while protecting the cells against oxidative stress-induced cellular senescence.
-
Complete Absence of Hematological or Hormonal Toxicity: Unlike full-length erythropoietin, MLPH produced no stimulation of erythroid progenitor cells, confirming it does not elevate red blood cell production. Furthermore, because the peptide operates independently of androgen receptors or 5-alpha reductase, it displayed zero anti-androgenic side effects, establishing its biological suitability for both male and female pattern hair loss.
“The MLPH peptide developed in this study represents a novel, safe, mechanism-based therapeutic candidate that overcomes the clinical limitations of recombinant EPO. By specifically activating EPOR-linked IGF-1 signaling in dermal papilla cells without inducing erythropoietic side effects, MLPH drives human hair shaft elongation and promotes anagen induction in both men and women.”— Research Consortium, DGIST and Kyungpook National University School of Medicine.
When Will It Be Available?
-
Current Stage: Completed computational design, in vitro human dermal papilla validation, and ex vivo human hair follicle organ culture studies published in Biomedicine & Pharmacotherapy.
-
Timeline: Animal disease model validation and preclinical pharmacokinetic formulation are advancing throughout late 2026, with Phase 1 human safety and localized topical tolerability trials targeted for 2027 to 2028, and prescription or clinical aesthetic translation anticipated by 2029 to 2030.
How you can benefit from this treatment now
-
The Shift to Peptide Growth Regulators: This discovery highlights that the next wave of hair loss therapeutics is shifting toward tissue-specific peptides that trigger native growth factors like IGF-1 directly at the dermal papilla, bypassing systemic hormonal blockade.
-
Support Endogenous Follicular IGF-1 Today: While targeted peptides like MLPH move through regulatory development, you can support native IGF-1 expression in scalp dermal papilla cells through evidence-based lifestyle and mechanical interventions. Controlled studies confirm that daily 4-minute circular manual scalp massage increases mechanical strain on dermal papilla cells, upregulating local IGF-1 and Wnt signaling.
-
Maintain Follicular Micronutrient Status: The intracellular signaling cascades stimulated by IGF-1 rely on cellular zinc, magnesium, and bioavailable amino acids for ribosomal protein synthesis. Maintaining balanced micronutrient levels prevents metabolic bottlenecks that can hinder hair matrix division.
-
Pair Scalp Topicals with Gentle Micro-Needling: Peptide chains require transdermal delivery past the stratum corneum to reach dermal papilla receptors. Performing a gentle 0.5 mm shallow scalp dermastamp once weekly creates microscopic channels that enhance the penetration of current growth-factor and peptide serums down into the hair bulb.
-
Avoid Unverified Grey-Market Research Peptides: Do not purchase unverified chemical vials labeled as “MLPH peptide” or uncharacterized EPO fragments from online chemical suppliers. Synthesizing active peptides requires strict stereochemical purity; unregulated mixtures degrade rapidly and pose serious risks of sterile abscesses or acute allergic contact dermatitis.
Action: Incorporate a gentle, circular fingertip scalp massage for 4 minutes each evening across thinning areas to stimulate mechanical tissue tension and encourage native IGF-1 production in your dermal papilla cells.